Americans at risk for alcohol-drug interactions

Healthcare providers need to help patients understand how alcohol can interact with their medications, according to a study from the National Institutes of Health and published in the February 2015 issue of Alcoholism: Clinical and Experimental Research. » Read more about the study

[BLOG]: Biosimilar confusion and insights

Renewed activity on the regulation of biologics has again raised issues for both state and federal policy makers while leading to continuing confusion among healthcare practice or administrative stakeholders with a responsibility for patient care. » Read for more clarity on the issue

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.

Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

[BLOG]: Pipeline advancement responsible for upturn in global pharma R&D

The increase in R&D spending was partly due to drug makers advancing their pipeline programs into later-stage clinical trials, which are generally more costly. Despite the sector increase in R&D spending, a number of large pharmaceutical firms pulled back on clinical investment in 2013. » What did AstraZeneca and Bayer spend on R&D?

• ER opioid analgesic with abuse-deterrent properties approved by FDA

• [BLOG]: Cost containment through use of generic medications

RESOURCES

Latest Clinical News